Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Medical Care|September 22, 2001
Multivariate matching and bias reduction in the surgical outcomes studyJ H Silber, P R Rosenbaum, M E Trudeau, et al.Current Oncology (Toronto, Ont.)|November 11, 2020
Reimbursement recommendations for cancer drugs supported by phase II evidence in CanadaY Y R Li, H Mai, M E Trudeau, et al.Current Oncology (Toronto, Ont.)|May 3, 2018
Factors associated with imaging in patients with early breast cancer after initial treatmentK Enright, T Desai, R Sutradhar, et al.Current Oncology (Toronto, Ont.)|February 21, 2009
A framework for the organization and delivery of systemic treatmentT Vandenberg, N Coakley, J Nayler, et al.Breast Cancer Research and Treatment|June 27, 2003
Hormone replacement therapy after treatment for breast cancer: physicians' attitudes towards randomized trialsM E Del Giudice, C A Sawka, K I Pritchard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicinD J Stewart, W K Evans, F A Shepherd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group studyT A Vandenberg, K I Pritchard, E A Eisenhauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials GroupM E Trudeau, E A Eisenhauer, B P Higgins, et al.Annals of Surgical Oncology|July 14, 2000
Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival modelD R McCready, J A Chapman, W M Hanna, et al.Breast Cancer Research and Treatment|January 1, 1992
A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancerJ A Chapman, M E Trudeau, K I Pritchard, et al.Pageof 4